Gestational trophoblastic disease (GTD)
The gestational trophoblastic disease (GTD) service at Charing Cross Hospital is a highly specialist service providing comprehensive registration, screening and clinical management for all forms of the disease.
Our internationally renowned GTD team are world leaders in the investigation and treatment of these rare conditions. Charing Cross Hospital is one of only two hospitals in the UK designated to treat GTD – registering around 1,200 women and treating around 120 women. We have a 100 per cent cure rate for patients identified through our registration and screening facility. Our service has the largest database of GTD patients in the world, holding records of over 35,000 women with the condition. This provides excellent data for research and audit, leading to excellent outcomes, improved treatment and better services for patients.
Conditions and treatments
GTD is a general term used to cover several diseases that occur during or following pregnancy. These include non-malignant (non-cancerous) partial and complete hydatidiform mole and the malignant (cancerous) invasive mole, as well as choriocarcinoma, and placental site trophoblastic tumour.
Most patients will not have heard of molar pregnancies, trophoblasts or choriocarcinoma, prior to their diagnosis, and finding reliable advice on the internet can be challenging.
Ninety per cent of women with GTD will not need to be seen at the hospital and will be monitored via the postal system with access to our advisory service for results and advice. In some cases, further treatment is required. Treatment for GTD is usually chemotherapy (drug treatment), but surgery is sometimes an option.
We welcome short and long term placements for visiting doctors both nationally and internationally who have an interest in GTD. Nurses with an interest in GTD are also welcome to visit. Please contact firstname.lastname@example.org.
Patient drop-in sessions
Bi-monthly patient drop-in sessions are held in February, April, June, August, October and December each year. Newly diagnosed patients are invited to attend the sessions, which are held at Charing Cross Hospital. For further information please contact the advisory team on 020 3311 1409.
Further online resources
- Molar Pregnancy
- Cancer Treatment and Research Trust – Charing Cross Hospital – the Cancer Treatment and Research Trust is a charitable fund set up to enable us to undertake research into the diseases we diagnose and treat. Visit this site for further information about how you can support our research.
- International Society for the Study of Trophoblastic Diseases (ISSTD) – the ISSTD is the official medical agency for physicians treating hydatidiform mole, PSTT, and choriocarcinoma. It holds biennial symposia for its members, for more information please visit their website.
- Sheffield Trophoblastic Disease Centre – the Sheffield Trophoblastic Disease Centre screens for gestational trophoblastic tumours and a spectrum of disorders including hydatidiform mole and choriocarcinoma.
- My Molar Pregnancy – information, personal stories, and support for women with molar pregnancy. This site is for women with molar pregnancy or who want to know more about it, without the medical jargon. Here you'll find the help and support you need.
- Miscarriage Association – the Miscarriage Association provides support and information for anyone affected by miscarriage, ectopic pregnancy or molar pregnancy.
- Cancer Research UK
- General Enquiries
- 020 3311 1234
Read the full story
Pioneering software set to improve NHS imaging services across north west London
Imperial College Healthcare is one of six NHS trusts in north west London that have formed a new network to improve imaging services – including x-ray, MRI and CT scans – to enable better care for cancer, stroke and a wide range of other conditions.
Read the full story
Cutting edge radiotherapy equipment installed at Charing Cross Hospital
Cancer patients are benefitting from the next generation of radiotherapy treatment thanks to two new state of the art linear accelerator machines (LINACS) installed at Charing Cross Hospital.
Read the full story
Breath test shows promising results in diagnosing pancreatic cancer at an earlier stage
Researchers have found a simple breath test has been able to detect pancreatic cancer. This means the disease can be diagnosed at an earlier stage and by using a non-invasive method for the very first time.